Literature DB >> 25752295

Oral squamous cancer cell exploits hnRNP A1 to regulate cell cycle and proliferation.

Cheng Yu1, Jihua Guo1, Yu Liu2, Jun Jia1, Rong Jia1, Mingwen Fan1.   

Abstract

Oral squamous cell carcinoma (OSCC) is a common human malignant tumor with high mortality. So far, the molecular pathogenesis of OSCC remains largely unclear. Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 is an important multi-function splicing factor and closely related to tumorigenesis. hnRNP A1 is overexpressed in various tumors, and promotes aerobic glycolysis and elongation of telomere, but the function of hnRNP A1 in cell cycle and proliferation remains unclear. We found that hnRNP A1 was overexpressed in OSCC tissues, and was required for the growth of OSCC cells. Moreover, hnRNP A1 was highly expressed in the G2/M cell cycle phase. Knockdown of hnRNP A1 induced G2/M arrest. DNA microarray assay result showed that hnRNP A1 regulated the expression of a number of target genes associated with G2/M phase. Moreover, hnRNP A1 controlled the alternative splicing of CDK2 exon 5. These findings suggested that hnRNP A1 plays key roles in the regulation of cell cycle progression and pathogenesis of OSCC.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25752295     DOI: 10.1002/jcp.24956

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

1.  Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Authors:  Alexey G Mittenberg; Valeria O Kuzyk; Sergey V Shabelnikov; Daria P Gorbach; Alla N Shatrova; Olga A Fedorova; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2018-08-01       Impact factor: 4.534

2.  HNRNPA1 promotes recognition of splice site decoys by U2AF2 in vivo.

Authors:  Jonathan M Howard; Hai Lin; Andrew J Wallace; Garam Kim; Jolene M Draper; Maximilian Haeussler; Sol Katzman; Masoud Toloue; Yunlong Liu; Jeremy R Sanford
Journal:  Genome Res       Date:  2018-04-12       Impact factor: 9.043

Review 3.  The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer.

Authors:  Andrea Cerasuolo; Luigi Buonaguro; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Front Cell Dev Biol       Date:  2020-06-12

4.  HnRNPA1 interacts with G-quadruplex in the TRA2B promoter and stimulates its transcription in human colon cancer cells.

Authors:  Tatsuya Nishikawa; Yuki Kuwano; Yumiko Takahara; Kensei Nishida; Kazuhito Rokutan
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

5.  PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23.

Authors:  Xiaole Wang; Jihua Guo; Xiaoxuan Che; Rong Jia
Journal:  Int J Biol Sci       Date:  2019-05-07       Impact factor: 6.580

6.  p300-Catalyzed Lysine Crotonylation Promotes the Proliferation, Invasion, and Migration of HeLa Cells via Heterogeneous Nuclear Ribonucleoprotein A1.

Authors:  Xuesong Han; Xudong Xiang; Hongying Yang; Hongping Zhang; Shuang Liang; Jie Wei; Jing Yu
Journal:  Anal Cell Pathol (Amst)       Date:  2020-12-07       Impact factor: 2.916

7.  Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma.

Authors:  Liu Peiqi; Guo Zhaozhong; Yin Yaotian; Jia Jun; Guo Jihua; Jia Rong
Journal:  Int J Med Sci       Date:  2016-06-30       Impact factor: 3.738

Review 8.  Phasing in on the cell cycle.

Authors:  Steven Boeynaems; Peter Tompa; Ludo Van Den Bosch
Journal:  Cell Div       Date:  2018-01-25       Impact factor: 5.130

9.  High expression of hnRNPA1 promotes cell invasion by inducing EMT in gastric cancer.

Authors:  Yahua Chen; Jun Liu; Wei Wang; Li Xiang; Jide Wang; Side Liu; Hongyan Zhou; Zheng Guo
Journal:  Oncol Rep       Date:  2018-02-16       Impact factor: 3.906

10.  Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.

Authors:  Hao Li; Jingwei Liu; Shixuan Shen; Di Dai; Shitong Cheng; Xiaolong Dong; Liping Sun; Xiaolin Guo
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.